Editas Medicine Inc (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 5,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $24.31, for a total transaction of $121,550.00. Following the completion of the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $121,550. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of Editas Medicine Inc (NASDAQ EDIT) traded down $0.35 during trading on Friday, reaching $32.00. The company’s stock had a trading volume of 929,900 shares, compared to its average volume of 1,520,000. The company has a market capitalization of $1,410.00 and a PE ratio of -9.88. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19. Editas Medicine Inc has a 52-week low of $13.12 and a 52-week high of $36.00.
Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The company had revenue of $6.28 million for the quarter, compared to the consensus estimate of $2.66 million. During the same period in the previous year, the company earned ($0.59) EPS. The firm’s revenue for the quarter was up 553.0% compared to the same quarter last year. analysts expect that Editas Medicine Inc will post -2.92 EPS for the current year.
Several analysts have issued reports on the company. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a report on Tuesday. Morgan Stanley restated an “equal weight” rating and set a $28.00 price objective (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. ValuEngine upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. BidaskClub upgraded Editas Medicine from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, Cann reiterated a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Editas Medicine has a consensus rating of “Hold” and an average target price of $26.73.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Editas Medicine by 12.5% in the second quarter. Vanguard Group Inc. now owns 2,177,146 shares of the company’s stock valued at $36,533,000 after acquiring an additional 241,973 shares during the period. State Street Corp raised its stake in shares of Editas Medicine by 305.4% in the second quarter. State Street Corp now owns 537,640 shares of the company’s stock valued at $9,022,000 after purchasing an additional 405,022 shares in the last quarter. Ark Investment Management LLC raised its stake in shares of Editas Medicine by 121.9% in the second quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock valued at $8,561,000 after purchasing an additional 280,265 shares in the last quarter. Northern Trust Corp raised its stake in shares of Editas Medicine by 245.9% in the second quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock valued at $6,261,000 after purchasing an additional 265,273 shares in the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of Editas Medicine in the third quarter valued at $7,497,000. 65.70% of the stock is owned by institutional investors.
WARNING: “Insider Selling: Editas Medicine Inc (NASDAQ:EDIT) CFO Sells 5,000 Shares of Stock” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thelincolnianonline.com/2018/01/13/insider-selling-editas-medicine-inc-edit-cfo-sells-121550-00-in-stock-updated-updated.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.